World Health Organization. Pre-exposure prophylaxis (PrEP). Global HIV Programme. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis. Accessed 3 Apr 2025.

AIDS Vaccine Advocacy Coalition. Oral PrEP: antiretroviral drugs in pill form. PrEP Watch. https://www.prepwatch.org/products/oral-prep. Updated December 11, 2024. Accessed 3 Apr 2025.

Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.

Article  PubMed  PubMed Central  Google Scholar 

Dimitrov DT, Mâsse BR, Donnell D. PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials. J Acquir Immune Defic Syndr. 2016;72:444–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang J, Li C, Xu J, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9:e254–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240054097. Published July 28, 2022. Accessed 3 Apr 2025

Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial [published correction appears in Lancet. 2022;399:1778]. Lancet. 2022;399:1779–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence. Draft guidance consultation. Cabotegravir for preventing HIV-1. https://www.nice.org.uk/guidance/GID-TA11304/documents/draft-guidance. Published September 2024. Accessed 3 Apr 2025.

Schnarrs PW, Gordon D, Martin-Valenzuela R, et al. Perceived social norms about oral PrEP use: differences between African-American, Latino and White gay, bisexual and other men who have sex with men in Texas. AIDS Behav. 2018;22:3588–602.

Article  PubMed  PubMed Central  Google Scholar 

Kelley CF, Acevedo-Quiñones M, Agwu AL, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392:1261–76.

Article  CAS  PubMed  Google Scholar 

Bekker L-G, Das M, Abdool Karim Q, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179–92.

Article  CAS  PubMed  Google Scholar 

Cochrane. Evidence synthesis - what is it and why do we need it? https://www.cochrane.org/news/evidence-synthesis-what-it-and-why-do-we-need-it. Published May 4, 2023. Accessed 3 Apr 2025.

Murchu EO, Marshall L, Teljeur C, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12:e048478.

Article  Google Scholar 

Huic M, Reinsperger I. Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements. AIHTA Project Report No.: 152; 2023. Vienna: HTA Austria – Austrian Institute for Health Technology Assessment GmbH. https://eprints.aihta.at/1436/1/HTA-Projektbericht_Nr.152.pdf. Accessed 2 Apr 2025.

Brady M, Rodger A, Asboe D, et al. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. HIV Med. 2019;20(suppl 2):s2-80.

PubMed  Google Scholar 

Hanscom B, Hughes JP, Williamson BD, Donnell D. Adaptive non-inferiority margins under observable non-constancy. Stat Methods Med Res. 2019;28:3318–32.

Article  PubMed  Google Scholar 

Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14:1055–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90.

Article  PubMed  Google Scholar 

Molina J-M, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46.

Article  CAS  PubMed  Google Scholar 

Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.

Article  CAS  PubMed  Google Scholar 

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.

Article  PubMed  PubMed Central  Google Scholar 

McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.

Article  PubMed  PubMed Central  Google Scholar 

Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parienti J-J. On-demand PrEP efficacy: forgiveness or timely dosing. Lancet HIV. 2020;7:e79-80.

Article  PubMed  Google Scholar 

Hanscom B, Janes HE, Guarino PD, et al. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73:606–8.

Article  PubMed  PubMed Central  Google Scholar 

Chapin-Bardales J, Haaland R, Martin A, et al. HIV pre-exposure prophylaxis persistence and adherence among men who have sex with men in four US cities. J Acquir Immune Defic Syndr. 2023;93:34–41.

Article  PubMed  PubMed Central  Google Scholar 

Holloway IW, Dougherty R, Gildner J, et al. Brief report: PrEP uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. J Acquir Immune Defic Syndr. 2017;74:15–20.

Article  PubMed  PubMed Central  Google Scholar 

Wood S, Gross R, Shea JA, et al. Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav. 2019;23:2719–29.

Article  PubMed  PubMed Central  Google Scholar 

Selfridge M, Card KG, Lundgren K, et al. Exploring nurse-led HIV pre-exposure prophylaxis in a community health care clinic. Public Health Nurs. 2020;37:871–9.

Article  PubMed  Google Scholar 

Antonini M, da Silva IE, Elias HC, Gerin L, Oliveira AC, Reis RK. Barriers to pre-exposure prophylaxis (PrEP) use for HIV: an integrative review. Rev Bras Enferm. 2023;76: e20210963.

PubMed  PubMed Central  Google Scholar 

Lalley-Chareczko L, Clark D, Conyngham C, et al. Delivery of TDF/FTC for pre-exposure prophylaxis to prevent HIV-1 acquisition in young adult men who have sex with men and transgender women of color using a urine adherence assay. J Acquir Immune Defic Syndr. 2018;79:173–8.

Article  PubMed  Google Scholar 

Molina J-M, Ghosn J, Assoumou L, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9:e554–62.

Article  CAS  PubMed  Google Scholar 

Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11: e0157742.

Article  PubMed  PubMed Central  Google Scholar